• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Gastroenterology

CA19-9 kinetics may predict pancreatic cancer resectability

byRehan SaiyedandChaz Carrier
October 29, 2014
in Gastroenterology, Oncology, Surgery
Reading Time: 3 mins read
CA19-9 kinetics may predict pancreatic cancer resectability
Share on FacebookShare on Twitter

1. Both an absolute increase of pre-operative CA 19-9 levels exceeding 50 U/ml as well as rate of change greater than 1 U/ml/day were strongly associated with higher rates of unresectable disease.

2. Twenty-three percent of patients with resectable disease had a rate of change of CA 19-9 greater than 1 U/ml in the resectable group, with 77% in the group with unresectable disease.

Evidence Rating Level: 2 (Good)

Study Rundown: It is estimated that between 10% and 25% of patients who undergo surgical tumor resection for pancreatic adenocarcinoma are ultimately deemed to have unresectable disease, leaving patients unnecessarily subjected to the risks and complications associated with the surgical procedure as well as delaying the delivery of any palliative systemic therapy. Recent research has sought to identify pre-operative markers which could be predictive of unresectable disease. One such marker, sialylated Lewis carbohydrate antigen 19-9 (CA19-9), has been shown to be associated with more malignant disease in pancreatic adenocarcinoma. However, widespread utility of levels of CA19-9 for the advisement of surgical decision-making has been limited due to the lack of consensus with regards to a specific cutoff and the cases of biliary obstruction comorbid with disease, which elevates blood levels of the marker. This study consequently examined kinetics of CA19-9 and found that both absolute increases of levels greater than 50 U/ml as well as a rate of change greater than 1 U/ml/day were strongly associated with higher rates of unresectable disease. There was no association found between the kinetics of CA19-9 and survival in resectable disease. This study aids in potentially identifying a pre-operative means to recognize unresectable pancreatic adenocarcinoma. However, the study is limited by its retrospective nature, small sample size, and cases which spanned 16 years, not accounting for potential changes in surgical indications and technique. Inconsistency in pre-operative CA19-9 measurement timing may also have introduced error into both the measured absolute change and rate of change in CA19-9 levels.

Click to read the study in Annals of Surgical Oncology

Relevant Reading: Utility of Tumor Markers in Determining Resectability of Pancreatic Cancer

RELATED REPORTS

2 Minute Medicine Rewind July 13, 2026

New targeted therapy daraxonrasib improves survival in pancreatic cancer

2 Minute Medicine: Pharma Roundup – Geopolitical instability in the Strait of Hormuz threatens global generic drug supply, daraxonrasib improves pancreatic cancer survival, sparsentan (Filspari) approved for focal segmental glomerulosclerosis, glucagon-like peptide-1 receptor agonists linked to reduced substance use disorders, and orforglipron (Foundayo) expands oral weight loss therapy options

In-Depth [retrospective]: A total of 72 patients who underwent exploratory surgery via laparotomy or diagnostic laparoscopy for potentially resectable pancreatic adenocarcinoma were included in the analysis. All patients underwent surgery at the University of California, Davis Medical Center between 1996 and 2012. Patients were selected on the basis of having, at a minimum, 2 preoperative levels of CA19-9 in their records. A suitable threshold of the absolute change in CA pre-operatively was determined to be ≥50 U/mL and the rate of change was ≥1 U/ml/day by receiver operating characteristic (ROC) curve analysis. Of patients with resectable disease, only 26% had changes in levels of CA19-9 exceeding 50 U/ml, compared to 60% in the unresectable group (p = 0.004). A rate of change in pre-operative CA19-9 levels ≥1 U/ml/day was also a strong predictor an unresectable tumor, with 23% of patients in the resectable group having a rate of change in CA19-9 exceeding 1 U/ml/day, compared to 77% in the group with unresectable disease (p=0.001). By Kaplan-Meir survival analysis, both the change in CA 19-9 < 50 U/ml and rate of change < 1 U/ml were shown to be predictive of increased survival (p = 0.039 and p = 0.019, respectively). However, neither variable was predictive of survivorship when isolating analysis to those with resectable disease only.

More from this author: Robotic adnexal surgeries may have more complications than laparoscopic, Subtype of metastatic esophageal cancer not a contraindication to surgery, Coronary angioplasty safe and effective at facilities without on-site cardiothoracic surgery

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: CA19-9pancreatic cancer
Previous Post

7 tesla breast MRI may improve assessment of suspicious masses

Next Post

Noninvasive imaging method detects and evaluates size of metastases

RelatedReports

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial
Weekly Rewinds

2 Minute Medicine Rewind July 13, 2026

July 13, 2026
Oncology

New targeted therapy daraxonrasib improves survival in pancreatic cancer

May 5, 2026
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Pharma

2 Minute Medicine: Pharma Roundup – Geopolitical instability in the Strait of Hormuz threatens global generic drug supply, daraxonrasib improves pancreatic cancer survival, sparsentan (Filspari) approved for focal segmental glomerulosclerosis, glucagon-like peptide-1 receptor agonists linked to reduced substance use disorders, and orforglipron (Foundayo) expands oral weight loss therapy options

May 4, 2026
Many new pediatric asthma cases attributable to obesity
Chronic Disease

GLP-1 receptor agonists show little effect on obesity-related cancer risk

December 8, 2025
Next Post
Noninvasive imaging method detects and evaluates size of metastases

Noninvasive imaging method detects and evaluates size of metastases

Repeat bone mineral density testing may not improve prediction of fracture outcomes

Milk consumption paradoxically linked to increased risk of fractures and mortality

Blood type correlates with egg reserve in infertile women

Double-unit cord-blood transplantation does not aid survival in children with hematologic malignancy

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Daraxonrasib showed antitumor activity in previously treated RAS-mutant non–small-cell lung cancer
  • The mortality in-hospital for patients undergoing elective catheter ablation for atrial fibrillation is low
  • Azacitidine–venetoclax improved event-free survival in induction-eligible AML
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.

2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in